Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Quanterix Corp (QTRX) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Quanterix Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 1503274.
Total stock buying since 2017: $22,207,106.
Total stock sales since 2017: $33,203,023.
Total stock option exercises since 2017: $2,762,895.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 509,013 | $2,873,839 | 0 | $0 | 0 | $0 |
| 2024 | 66,000 | $831,730 | 4,000 | $85,495 | 1,000 | $12,860 |
| 2023 | 20,200 | $501,970 | 0 | $0 | 23,335 | $67,438 |
| 2022 | 619,131 | $5,559,019 | 34,072 | $922,642 | 41,246 | $111,776 |
| 2021 | 0 | $0 | 252,762 | $14,571,348 | 75,337 | $1,228,763 |
| 2020 | 54,064 | $900,922 | 388,702 | $10,801,052 | 106,943 | $241,425 |
| 2019 | 0 | $0 | 175,446 | $3,364,934 | 51,661 | $121,212 |
| 2018 | 2,700 | $49,626 | 195,673 | $3,457,552 | 143,214 | $873,012 |
| 2017 | 766,000 | $11,490,000 | 0 | $0 | 46,671 | $106,409 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 509,013 | $2,873,839 | 0 | $0 | 0 | $0 |
| 2024-08 | 66,000 | $831,730 | 0 | $0 | 0 | $0 |
| 2024-05 | 0 | $0 | 1,500 | $25,470 | 0 | $0 |
| 2024-04 | 0 | $0 | 1,000 | $23,500 | 1,000 | $12,860 |
| 2024-02 | 0 | $0 | 1,500 | $36,525 | 0 | $0 |
| 2023-09 | 20,200 | $501,970 | 0 | $0 | 0 | $0 |
| 2023-06 | 0 | $0 | 0 | $0 | 23,335 | $67,438 |
| 2022-08 | 619,131 | $5,559,019 | 884 | $13,802 | 0 | $0 |
| 2022-07 | 0 | $0 | 2,213 | $37,354 | 0 | $0 |
| 2022-06 | 0 | $0 | 8,834 | $142,094 | 0 | $0 |
| 2022-05 | 0 | $0 | 1,078 | $24,238 | 0 | $0 |
| 2022-04 | 0 | $0 | 1,824 | $54,340 | 0 | $0 |
| 2022-03 | 0 | $0 | 4,288 | $130,354 | 0 | $0 |
| 2022-02 | 0 | $0 | 7,114 | $230,925 | 0 | $0 |
| 2022-01 | 0 | $0 | 7,837 | $289,535 | 41,246 | $111,776 |
| 2021-12 | 0 | $0 | 6,227 | $253,143 | 0 | $0 |
| 2021-11 | 0 | $0 | 19,511 | $1,072,460 | 10,718 | $204,928 |
| 2021-10 | 0 | $0 | 11,086 | $566,750 | 0 | $0 |
| 2021-09 | 0 | $0 | 16,226 | $800,364 | 0 | $0 |
| 2021-08 | 0 | $0 | 11,150 | $556,108 | 0 | $0 |
| 2021-07 | 0 | $0 | 24,618 | $1,411,592 | 9,806 | $216,908 |
| 2021-06 | 0 | $0 | 33,274 | $1,857,808 | 9,851 | $189,464 |
| 2021-05 | 0 | $0 | 12,868 | $683,723 | 0 | $0 |
| 2021-04 | 0 | $0 | 14,149 | $878,159 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-13 | Walt David R | Buy | 123,990 | 6.14 | 760,802 |
| 2025-06-12 | Walt David R | Buy | 36,010 | 6.22 | 224,162 |
| 2025-06-09 | Toloue Masoud (President & CEO) | Buy | 45,900 | 5.42 | 248,732 |
| 2025-06-09 | Walt David R | Buy | 78,131 | 5.34 | 417,219 |
| 2025-06-06 | Donnelly William P | Buy | 93,113 | 5.44 | 506,348 |
| 2025-06-06 | Walt David R | Buy | 131,869 | 5.43 | 716,576 |
| 2024-08-20 | Walt David R | Buy | 47,000 | 13.29 | 624,630 |
| 2024-08-13 | Toloue Masoud (President & CEO) | Buy | 19,000 | 10.90 | 207,100 |
| 2024-05-14 | Olson Laurie J | Sale | 1,500 | 16.98 | 25,470 |
| 2024-04-01 | Olson Laurie J | Sale | 1,000 | 23.50 | 23,500 |
| 2024-04-01 | Olson Laurie J | Option Ex | 1,000 | 12.86 | 12,860 |
| 2024-02-14 | Olson Laurie J | Sale | 1,500 | 24.35 | 36,525 |
| 2023-09-08 | Donnelly William P | Buy | 20,200 | 24.85 | 501,970 |
| 2023-06-07 | Meister Paul M | Option Ex | 23,335 | 2.89 | 67,438 |
| 2022-08-15 | Doyle Michael A (CFO and Treasurer) | Buy | 15,000 | 10.16 | 152,415 |
| 2022-08-12 | Toloue Masoud (President & CEO) | Buy | 105,000 | 10.43 | 1,095,150 |
| 2022-08-12 | Doyle Michael A (CFO and Treasurer) | Buy | 15,000 | 10.43 | 156,510 |
| 2022-08-11 | Hlavinka Sarah E. | Buy | 10,160 | 9.92 | 100,787 |
| 2022-08-10 | Madaus Martin D | Buy | 89,667 | 8.43 | 755,534 |
| 2022-08-10 | Walt David R | Buy | 150,000 | 8.62 | 1,293,450 |
| 2022-08-10 | Meister Paul M | Buy | 234,304 | 8.56 | 2,005,173 |
| 2022-08-01 | Toloue Masoud (President & CEO) | Sale | 446 | 15.62 | 6,964 |
| 2022-08-01 | Fry John J (General Counsel & Secretary) | Sale | 401 | 15.62 | 6,261 |
| 2022-08-01 | Doyle Michael A (CFO and Treasurer) | Sale | 37 | 15.62 | 577 |
| 2022-07-13 | Doyle Michael A (CFO and Treasurer) | Sale | 434 | 18.16 | 7,879 |
| 2022-07-05 | Toloue Masoud (President & CEO) | Sale | 432 | 16.57 | 7,157 |
| 2022-07-05 | Fry John J (General Counsel & Secretary) | Sale | 387 | 16.57 | 6,412 |
| 2022-07-05 | Hrusovsky E Kevin (Executive Chairman) | Sale | 960 | 16.57 | 15,906 |
| 2022-06-13 | Toloue Masoud (President & CEO) | Sale | 5,564 | 15.27 | 84,956 |
| 2022-06-02 | Fry John J (General Counsel & Secretary) | Sale | 756 | 17.47 | 13,210 |
| 2022-06-02 | Hrusovsky E Kevin (Executive Chairman) | Sale | 1,424 | 17.47 | 24,882 |
| 2022-05-02 | Fry John J (General Counsel & Secretary) | Sale | 429 | 22.48 | 9,646 |
| 2022-05-02 | Hrusovsky E Kevin (Executive Chairman) | Sale | 649 | 22.48 | 14,592 |
| 2022-04-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 261 | 29.79 | 7,775 |
| 2022-04-01 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 171 | 29.79 | 5,094 |
| 2022-04-01 | Fry John J (General Counsel & Secretary) | Sale | 524 | 29.79 | 15,611 |
| 2022-04-01 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 868 | 29.79 | 25,860 |
| 2022-03-23 | Duffy David C. (SVP R&D and CTO) | Sale | 3,266 | 30.00 | 97,980 |
| 2022-03-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 267 | 31.68 | 8,458 |
| 2022-03-01 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 166 | 31.68 | 5,258 |
| 2022-03-01 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 589 | 31.68 | 18,658 |
| 2022-02-09 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 318 | 34.97 | 11,120 |
| 2022-02-09 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 292 | 34.97 | 10,210 |
| 2022-02-09 | Fry John J (General Counsel & Secretary) | Sale | 481 | 34.97 | 16,820 |
| 2022-02-09 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 1,364 | 34.97 | 47,697 |
| 2022-02-04 | Duffy David C. (SVP R&D and CTO) | Sale | 3,266 | 30.91 | 100,952 |
| 2022-02-02 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 267 | 31.68 | 8,458 |
| 2022-02-02 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 166 | 31.68 | 5,258 |
| 2022-02-02 | Fry John J (General Counsel & Secretary) | Sale | 371 | 31.68 | 11,752 |
| 2022-02-02 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 589 | 31.68 | 18,658 |
| 2022-01-31 | Duffy David C. (SVP R&D and CTO) | Sale | 3,266 | 30.00 | 97,980 |
| 2022-01-03 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 355 | 41.91 | 14,876 |
| 2022-01-03 | Duffy David C. (SVP R&D and CTO) | Option Ex | 41,246 | 2.71 | 111,776 |
| 2022-01-03 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 149 | 41.91 | 6,244 |
| 2022-01-03 | Fry John J (General Counsel & Secretary) | Sale | 352 | 41.91 | 14,751 |
| 2022-01-03 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 3,715 | 41.91 | 155,684 |
| 2021-12-29 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 40.71 | 67,863 |
| 2021-12-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 353 | 40.63 | 14,343 |
| 2021-12-01 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 147 | 40.63 | 5,972 |
| 2021-12-01 | Fry John J (General Counsel & Secretary) | Sale | 350 | 40.63 | 14,221 |
| 2021-12-01 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 3,710 | 40.63 | 150,744 |
| 2021-11-19 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 45.54 | 75,915 |
| 2021-11-10 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 5,000 | 55.13 | 275,650 |
| 2021-11-05 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 8,535 | 57.82 | 493,502 |
| 2021-11-05 | Mattoon Dawn (Sr. VP, Diagnostics) | Option Ex | 10,718 | 19.12 | 204,928 |
| 2021-11-04 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 1 | 57.00 | 57 |
| 2021-11-02 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 333 | 52.77 | 17,572 |
| 2021-11-02 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 139 | 52.77 | 7,335 |
| 2021-11-02 | Fry John J (General Counsel & Secretary) | Sale | 331 | 52.77 | 17,467 |
| 2021-11-02 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 3,505 | 52.77 | 184,962 |
| 2021-10-22 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 5,000 | 50.94 | 254,695 |
| 2021-10-15 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 51.47 | 85,800 |
| 2021-10-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 342 | 51.20 | 17,510 |
| 2021-10-01 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 143 | 51.20 | 7,321 |
| 2021-10-01 | Fry John J (General Counsel & Secretary) | Sale | 340 | 51.20 | 17,408 |
| 2021-10-01 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 3,594 | 51.20 | 184,016 |
| 2021-09-30 | Hrusovsky E Kevin (Chairman and CEO) | Sale | 5,000 | 48.38 | 241,910 |
| 2021-09-22 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 47.72 | 79,549 |
| 2021-09-02 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 49.95 | 249,750 |
| 2021-09-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 353 | 50.27 | 17,743 |
| 2021-09-01 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 147 | 50.27 | 7,388 |
| 2021-09-01 | Fry John J (General Counsel & Secretary) | Sale | 350 | 50.27 | 17,592 |
| 2021-09-01 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 3,709 | 50.27 | 186,432 |
| 2021-08-20 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 46.13 | 76,898 |
| 2021-08-16 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 47.62 | 238,080 |
| 2021-08-03 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 346 | 53.79 | 18,610 |
| 2021-08-03 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 145 | 53.79 | 7,799 |
| 2021-08-03 | Fry John J (General Counsel & Secretary) | Sale | 344 | 53.79 | 18,503 |
| 2021-08-03 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 3,648 | 53.79 | 196,218 |
| 2021-07-29 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 54.03 | 270,160 |
| 2021-07-14 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 57.77 | 96,302 |
| 2021-07-13 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 57.55 | 287,760 |
| 2021-07-02 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 347 | 58.46 | 20,284 |
| 2021-07-02 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 146 | 58.46 | 8,534 |
| 2021-07-02 | Fry John J (General Counsel & Secretary) | Sale | 346 | 58.46 | 20,226 |
| 2021-07-02 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 3,658 | 58.46 | 213,835 |
| 2021-07-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 8,454 | 58.49 | 494,491 |
| 2021-07-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Option Ex | 9,806 | 22.12 | 216,908 |
| 2021-06-23 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 62.11 | 103,537 |
| 2021-06-15 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 696 | 64.33 | 44,776 |
| 2021-06-14 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 66.62 | 333,095 |
| 2021-06-07 | Dekkers Marijn E | Sale | 9,051 | 55.91 | 506,050 |
| 2021-06-07 | Dekkers Marijn E | Option Ex | 4,732 | 23.12 | 109,403 |
| 2021-06-04 | Dekkers Marijn E | Sale | 7,610 | 55.05 | 418,915 |
| 2021-06-04 | Dekkers Marijn E | Option Ex | 5,119 | 15.64 | 80,061 |
| 2021-06-02 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 49.22 | 246,085 |
| 2021-06-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 243 | 48.32 | 11,741 |
| 2021-06-01 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 153 | 48.32 | 7,392 |
| 2021-06-01 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 3,854 | 48.32 | 186,217 |
| 2021-05-28 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 51.00 | 85,017 |
| 2021-05-13 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 46.38 | 231,910 |
| 2021-05-03 | Chaubal Amol (Chief Financial Officer) | Sale | 178 | 58.95 | 10,492 |
| 2021-05-03 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 234 | 58.95 | 13,793 |
| 2021-05-03 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,789 | 59.17 | 342,511 |
| 2021-04-20 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 58.26 | 291,300 |
| 2021-04-08 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 65.38 | 326,890 |
| 2021-04-01 | Chaubal Amol (Chief Financial Officer) | Sale | 165 | 62.66 | 10,338 |
| 2021-04-01 | Mattoon Dawn (Sr. VP, Diagnostics) | Sale | 215 | 62.66 | 13,471 |
| 2021-04-01 | Roskey Mark T. (SVP, Strategic Partnerships) | Sale | 136 | 62.66 | 8,521 |
| 2021-04-01 | Fry John J (General Counsel & Secretary) | Sale | 201 | 62.66 | 12,594 |
| 2021-04-01 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 3,432 | 62.66 | 215,045 |
| 2021-03-19 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 58.36 | 97,286 |
| 2021-03-16 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 60.97 | 304,845 |
| 2021-03-08 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 66.46 | 332,290 |
| 2021-03-01 | Chaubal Amol (Chief Financial Officer) | Sale | 166 | 81.55 | 13,537 |
| 2021-03-01 | Mattoon Dawn (Sr. VP, Research Products) | Sale | 217 | 81.55 | 17,696 |
| 2021-03-01 | Roskey Mark T. (SVP, Commercial & Accelerator) | Sale | 137 | 81.55 | 11,172 |
| 2021-03-01 | Fry John J (General Counsel & Secretary) | Sale | 202 | 81.55 | 16,473 |
| 2021-03-01 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 3,443 | 81.55 | 280,783 |
| 2021-02-19 | Chaubal Amol (Chief Financial Officer) | Sale | 733 | 89.95 | 65,937 |
| 2021-02-19 | Mattoon Dawn (Sr. VP, Research Products) | Sale | 871 | 89.95 | 78,350 |
| 2021-02-19 | Roskey Mark T. (SVP, Commercial & Accelerator) | Sale | 670 | 89.95 | 60,269 |
| 2021-02-19 | Fry John J (General Counsel & Secretary) | Sale | 871 | 89.95 | 78,350 |
| 2021-02-19 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 3,493 | 89.96 | 314,233 |
| 2021-02-18 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 84.50 | 422,480 |
| 2021-02-11 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 79.62 | 132,726 |
| 2021-02-09 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 77.95 | 389,765 |
| 2021-02-01 | Chaubal Amol (Chief Financial Officer) | Sale | 133 | 68.21 | 9,072 |
| 2021-02-01 | Mattoon Dawn (Sr. VP, Research Products) | Sale | 182 | 68.21 | 12,414 |
| 2021-02-01 | Roskey Mark T. (SVP, Commercial & Accelerator) | Sale | 105 | 68.21 | 7,162 |
| 2021-02-01 | Fry John J (General Counsel & Secretary) | Sale | 163 | 68.21 | 11,118 |
| 2021-02-01 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 8,249 | 66.71 | 550,266 |
| 2021-01-25 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 77.92 | 389,625 |
| 2021-01-22 | Duffy David C. (SVP R&D and CTO) | Sale | 1,667 | 79.29 | 132,176 |
| 2021-01-19 | Hrusovsky E Kevin (Chairman, President & CEO) | Sale | 5,000 | 75.06 | 375,325 |
| 2021-01-11 | Dekkers Marijn E | Sale | 44,962 | 49.13 | 2,208,938 |
| 2021-01-11 | Dekkers Marijn E | Option Ex | 44,962 | 13.73 | 617,463 |
| 2021-01-05 | Chaubal Amol (Chief Financial Officer) | Sale | 124 | 44.13 | 5,472 |
| 2021-01-05 | Mattoon Dawn (Sr. VP, Research Products) | Sale | 170 | 44.13 | 7,502 |
| 2021-01-05 | Roskey Mark T. (SVP, Commercial & Accelerator) | Sale | 98 | 44.13 | 4,324 |
Insider trading activities including stock purchases, stock sales, and option exercises of QTRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Quanterix Corp (symbol QTRX, CIK number 1503274) see the Securities and Exchange Commission (SEC) website.